CRNX
Crinetics Pharmaceuticals, Inc. [CRNX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CRNX Stock Summary
Top 10 Correlated ETFs
CRNX
Top 10 Correlated Stocks
CRNX
In the News
CRNX Financial details
Company Rating
Sell
Market Cap
3.47B
Income
-212.55M
Revenue
4.01M
Book val./share
8.03
Cash/share
8.32
Dividend
-
Dividend %
-
Employees
290
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-11.05
Forward P/E
-
PEG
-5.77
P/S
536.43
P/B
-3.63
P/C
5.16
P/FCF
-20.73
Quick Ratio
13.71
Current Ratio
14.23
Debt / Equity
0.1
LT Debt / Equity
0.09
-
-
EPS (TTM)
-3.67
EPS next Y
-
EPS next Q
-
EPS this Y
19.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.47%
Revenue last 5Y
27.46%
Revenue Q/Q
-
EPS Q/Q
-10.89%
-
-
-
-
SMA20
7.14%
SMA50
21.62%
SMA100
50%
Inst Own
92.28%
Inst Trans
0.92%
ROA
-30%
ROE
62%
ROC
-0.35%
Gross Margin
100%
Oper. Margin
-4394%
Profit Margin
-4127%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
15.71-49.58
52W High
-12.31%
52W Low
+186.47%
RSI
48
Rel Volume
0.4
Avg Volume
808.4K
Volume
322.08K
Perf Week
-6.38%
Perf Month
1.11%
Perf Quarter
47.06%
Perf Half Y
46.61%
-
-
-
-
Beta
0.618
-
-
Volatility
1.55%, 2.71%
Prev Close
-2.36%
Price
42.97
Change
-1.74%
CRNX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.05 | 0 | 0.03 | 0.09 | 0.07 | |
| Net income per share | -2.05 | -2.39 | -2.78 | -3.08 | -3.69 | |
| Operating cash flow per share | -1.92 | -2.04 | -2.3 | -2.22 | -2.86 | |
| Free cash flow per share | -1.94 | -2.04 | -2.32 | -2.25 | -2.94 | |
| Cash per share | 4.9 | 5.61 | 8.68 | 6.43 | 9.62 | |
| Book value per share | -3.88 | -5.5 | -7.16 | -8.45 | 9.28 | |
| Tangible book value per share | 4.85 | 5.55 | 8.64 | 6.09 | 9.28 | |
| Share holders equity per share | -3.88 | -5.5 | -7.16 | -8.45 | 9.28 | |
| Interest debt per share | 0.23 | 0.16 | 0.1 | 0.14 | 0.89 | |
| Market cap | 606.55M | 429.62M | 1.09B | 951.27M | 2.07B | |
| Enterprise value | 571.07M | 340.55M | 894.35M | 920.62M | 2.06B | |
| P/E ratio | -12.24 | -5.9 | -10.23 | -5.95 | -9.63 | |
| Price to sales ratio | 508.42 | 6.05K | 1.01K | 200.82 | 514.87 | |
| POCF ratio | -13.08 | -6.93 | -12.33 | -8.26 | -12.42 | |
| PFCF ratio | -12.94 | -6.91 | -12.27 | -8.14 | -12.08 | |
| P/B Ratio | -6.47 | -2.56 | -3.97 | -2.17 | 3.83 | |
| PTB ratio | -6.47 | -2.56 | -3.97 | -2.17 | 3.83 | |
| EV to sales | 478.69 | 4.8K | 829.63 | 194.35 | 514.08 | |
| Enterprise value over EBITDA | -10.61 | -4.54 | -8.3 | -5.48 | -9.31 | |
| EV to operating cash flow | -12.31 | -5.49 | -10.1 | -7.99 | -12.4 | |
| EV to free cash flow | -12.18 | -5.47 | -10.05 | -7.88 | -12.06 | |
| Earnings yield | -0.08 | -0.17 | -0.1 | -0.17 | -0.1 | |
| Free cash flow yield | -0.08 | -0.14 | -0.08 | -0.12 | -0.08 | |
| Debt to equity | -0.06 | -0.03 | -0.01 | -0.01 | 0.1 | |
| Debt to assets | 0.04 | 0.03 | 0.01 | 0.01 | 0.08 | |
| Net debt to EBITDA | 0.66 | 1.19 | 1.83 | 0.18 | 0.01 | |
| Current ratio | 14.79 | 16.92 | 21.55 | 12.45 | 13.07 | |
| Interest coverage | 0 | 0 | 0 | -38.89 | 0 | |
| Income quality | 0.92 | 0.84 | 0.82 | 0.7 | 0.78 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 11.33 | 253.89 | 22.75 | 8.95 | 14.48 | |
| Research and developement to revenue | 34.79 | 802.79 | 78.16 | 27.49 | 41.72 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0.01 | 0.03 | |
| Capex to revenue | -0.41 | -2.62 | -0.4 | -0.35 | -1.17 | |
| Capex to depreciation | -0.55 | -0.2 | -0.47 | -1.68 | -4.27 | |
| Stock based compensation to revenue | 5.28 | 146.86 | 16.1 | 5.97 | 10.2 | |
| Graham number | 13.37 | 17.22 | 21.15 | 24.19 | 27.78 | |
| ROIC | 0.63 | 0.47 | 0.4 | 0.38 | -0.35 | |
| Return on tangible assets | -0.38 | -0.4 | -0.3 | -0.45 | -0.34 | |
| Graham Net | 4.36 | 5.15 | 8.33 | 5.78 | 8.08 | |
| Working capital | 115M | 167M | 328.73M | 317.46M | 530.21M | |
| Tangible asset value | 117.14M | 168.92M | 331.94M | 316.33M | 539.11M | |
| Net current asset value | 110.1M | 162.97M | 325.65M | 309.34M | 477.91M | |
| Invested capital | -0.06 | -0.03 | -0.01 | -0.01 | 0.1 | |
| Average receivables | 1.48M | 1.61M | 1.93M | 2.23M | 5.89M | |
| Average payables | 3.48M | 5.54M | 7.03M | 7.68M | 6.72M | |
| Average inventory | -689K | -1.61M | 3.12M | 4.04M | 0 | |
| Days sales outstanding | 421.6 | 9.42K | 687 | 186.85 | 850.51 | |
| Days payables outstanding | 1.8K | 35.78 | 2.45K | 1.81K | 2.18K | |
| Days of inventory on hand | -451.9 | -11.74 | 2.33K | 0 | 0 | |
| Receivables turnover | 0.87 | 0.04 | 0.53 | 1.95 | 0.43 | |
| Payables turnover | 0.2 | 10.2 | 0.15 | 0.2 | 0.17 | |
| Inventory turnover | -0.81 | -31.1 | 0.16 | 0 | 0 | |
| ROE | 0.53 | 0.43 | 0.39 | 0.36 | -0.4 | |
| Capex per share | -0.02 | -0.01 | -0.01 | -0.03 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0.05 | 0.02 | 0.01 | 0 | |
| Net income per share | -0.79 | -0.82 | -0.94 | -1.01 | -0.9 | |
| Operating cash flow per share | -0.65 | -0.76 | -0.84 | -0.73 | -0.57 | |
| Free cash flow per share | -0.66 | -0.76 | -0.85 | -0.79 | -0.59 | |
| Cash per share | 6.21 | 5.49 | 4.87 | 9.76 | 8.32 | |
| Book value per share | -8.16 | -9 | 4.68 | -10.45 | 8.03 | |
| Tangible book value per share | 5.88 | 5.2 | 4.68 | 9.64 | 8.03 | |
| Share holders equity per share | -8.16 | -9 | 4.68 | -10.45 | 8.03 | |
| Interest debt per share | 0.09 | 0.02 | 0.05 | 0.92 | 0.77 | |
| Market cap | 985.25M | 865.76M | 978.04M | 1.69B | 2.39B | |
| Enterprise value | 954.61M | 827.39M | 941.05M | 1.6B | 2.39B | |
| P/E ratio | -5.81 | -4.92 | -4.8 | -7.35 | -9.94 | |
| Price to sales ratio | 1.39K | 323.17 | 989.91 | 4.88K | 0 | |
| POCF ratio | -27.98 | -21.26 | -21.38 | -40.87 | -62.03 | |
| PFCF ratio | -27.77 | -21.25 | -21.27 | -37.68 | -60.56 | |
| P/B Ratio | -2.24 | -1.78 | 3.85 | -2.85 | 4.43 | |
| PTB ratio | -2.24 | -1.78 | 3.85 | -2.85 | 4.43 | |
| EV to sales | 1.35K | 308.84 | 952.48 | 4.62K | 0 | |
| Enterprise value over EBITDA | -20.07 | -17.25 | -17.85 | -27.11 | -38.24 | |
| EV to operating cash flow | -27.11 | -20.32 | -20.58 | -38.68 | -61.95 | |
| EV to free cash flow | -26.9 | -20.31 | -20.47 | -35.66 | -60.48 | |
| Earnings yield | -0.04 | -0.05 | -0.05 | -0.03 | -0.03 | |
| Free cash flow yield | -0.04 | -0.05 | -0.05 | -0.03 | -0.02 | |
| Debt to equity | -0.01 | -0.01 | 0.01 | -0.09 | 0.1 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.08 | 0.08 | |
| Net debt to EBITDA | 0.64 | 0.8 | 0.7 | 1.54 | 0.05 | |
| Current ratio | 12.45 | 11.6 | 8.73 | 14.23 | 13.07 | |
| Interest coverage | -24.98 | 24.19 | 0 | 0 | 0 | |
| Income quality | 0.78 | 0.89 | 0.9 | 0.72 | 0.64 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 15.9 | 4.55 | 13.51 | 44.75 | 0 | |
| Research and developement to revenue | 52.17 | 14.36 | 41.13 | 126.7 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0.01 | 0.08 | 0.02 | |
| Capex to revenue | -0.39 | -0.01 | -0.24 | -10.12 | 0 | |
| Capex to depreciation | -0.98 | -0.06 | -0.85 | -12.82 | -3.57 | |
| Stock based compensation to revenue | 11.21 | 3.02 | 10.3 | 31.93 | 0 | |
| Graham number | 12.03 | 12.86 | 9.95 | 15.42 | 12.72 | |
| ROIC | 0.1 | 0.1 | -0.2 | 0.12 | -0.1 | |
| Return on tangible assets | -0.12 | -0.14 | -0.17 | -0.09 | -0.09 | |
| Graham Net | 5.58 | 4.88 | 4.33 | 8.16 | 6.99 | |
| Working capital | 317.46M | 279.08M | 252.2M | 535.3M | 530.21M | |
| Tangible asset value | 316.33M | 280.33M | 254.12M | 547.75M | 539.11M | |
| Net current asset value | 309.34M | 271.72M | 245.67M | 481.97M | 477.91M | |
| Invested capital | -0.01 | -0.01 | 0.01 | -0.09 | 0.1 | |
| Average receivables | 2.39M | 2.39M | 2.37M | 7.01M | 10.5M | |
| Average payables | 6.38M | 6.39M | 5.37M | 5.34M | 6.2M | |
| Average inventory | 2.98M | -1.17M | 6.39M | 1.75M | -5.82M | |
| Days sales outstanding | 307.83 | 78.91 | 216.98 | 3.03K | 0 | |
| Days payables outstanding | 1.6K | 1.33K | 1.1K | 1.93K | 2.25K | |
| Days of inventory on hand | 0 | -531.18 | 3.42K | -3.84K | 0 | |
| Receivables turnover | 0.29 | 1.14 | 0.41 | 0.03 | 0 | |
| Payables turnover | 0.06 | 0.07 | 0.08 | 0.05 | 0.04 | |
| Inventory turnover | 0 | -0.17 | 0.03 | -0.02 | 0 | |
| ROE | 0.1 | 0.09 | -0.2 | 0.1 | -0.11 | |
| Capex per share | -0.01 | 0 | 0 | -0.06 | -0.01 |
CRNX Frequently Asked Questions
What is Crinetics Pharmaceuticals, Inc. stock symbol ?
Crinetics Pharmaceuticals, Inc. is a US stock , located in San diego of Ca and trading under the symbol CRNX
What is Crinetics Pharmaceuticals, Inc. stock quote today ?
Crinetics Pharmaceuticals, Inc. stock price is $42.97 today.
Is Crinetics Pharmaceuticals, Inc. stock public?
Yes, Crinetics Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 808.4K
- Market Capitalization 3.47B
- Employee 290
- CEO Dr. R. Scott Struthers Ph.D.
- Headquarters San Diego,CA,US
- IPO Date 2018-07-18
-
Website
https://www.crinetics.com 
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
